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Abstract  
Reduction in the expression and activity of a well-known proto-oncogene, Myc, has a beneficial 
effect on mouse health and survival to old age, in part independently of cancer impact, a recent 
study reveals. Is this new anti-ageing intervention pointing a way towards new treatments for 
age-related diseases? 
 
Text 
The time an organism stays alive (lifespan) and healthy (healthspan) is, for most animals, 
limited by an intrinsic process of deterioration that is ageing. In humans, age is the major risk 
factor for the predominant killer and chronic diseases, including cancer and cardiovascular 
disease, and for debilitating pathologies, such as neurodegeneration. The proportion of older 
people in many populations is rising fast, with individuals over 85 years old the most rapidly 
expanding age-group in developed countries1. Because the major burden of ill health is falling 
on older people, ameliorating the effects of ageing has become an urgent priority for research.  
The hallmarks of ageing are becoming well delineated and are complex, but the process has 
proved to be malleable, because both healthspan and lifespan can be extended by genetic, 
environmental and pharmacological interventions2. Recent work by Hofmann, Zhao and co-
workers in the journal Cell adds a new, and intriguing, intervention to the current anti-ageing 
arsenal, by showing that mice heterozygous for Myc loss-of-function have increased lifespan 
and healthspan3. 
 
Investigation of Myc started in the late 1970s with the discovery that retrovirally induced chicken 
tumours contained a new viral oncogene, v-Myc. The host genome contained a version of this 
gene, the Myc proto-oncogene, which contributes to the aetiology of many human cancers. Myc 
encodes a transcriptional regulator controlling the expression of a large portion of the genome to 
direct cell growth, proliferation, tumorogenesis and stem cell function4. Hofmann, Sedivy and co-
workers noticed that many of the cellular and organismal processes promoted by Myc are also 
present in ageing and age-related diseases, prompting them to examine ageing in a mouse 
where constitutively reduced activity of Myc was achieved by deletion of one of its copies from 
the genome3. 
Median lifespan of Myc+/- mice was extended relative to controls by 10.7% in males and 20.9% 
in females. The mutant mice also showed functional improvements, with lower levels of cardiac 
fibrosis, osteoporosis and more youthful levels of lipid metabolism and motor performance3. 
Such broad-spectrum protection against age-related changes argues that the extended healthy 
lifespan was not simply due to preservation of function of a specific tissue or prevention of a 
specific disease. Indeed, the incidence of the main cause of death, lymphoma, appeared to be 
unaffected in Myc+/- mice, although their lymphomas had progressed and spread less by the 
time that they died3. Furthermore, reduced Myc activity was previously shown to extend lifespan 
in Drosophila5, an invertebrate model where death is unlikely due to cancer. The broad-
spectrum effects and evolutionary conservation of Myc function in longevity support its potential 
as a basis for anti-ageing therapy in humans. 
 
Interestingly the Myc mutant mouse lacked some features of other long-lived mouse models, 
including altered content or distribution of fat, altered rates of cellular senescence, genotoxic 
stress or apoptosis, and not reduced fecundity. These phenotypes may therefore not contribute 
to increased lifespan or, alternatively, lowered Myc activity may act through different 
mechanisms to promote healthy ageing3. The transcriptome of Myc+/- mice showed preservation 
at later ages of youthful levels and patterns of expression of genes involved in lipid metabolism 
and immune function, both processes dysregulated during normal ageing. Myc is a major 
transcriptional regulator of ribosome biogenesis, and Myc+/- mice showed reduced content of 
ribosomal proteins, rRNA and reduced rates of translation, features often associated with anti-
ageing interventions3. The Myc+/- mice also had a higher metabolic rate, were more active, and 
consumed more food and water than controls.  
 
A relationship between reduced activity of Myc and other interventions that increase healthspan 
is implied by its relationship with the Forkhead Box O (FoxO) transcription factor family 
members. FoxO activity can extend healthy lifespan in invertebrate model organisms, and 
variants of FoxO genes are robustly linked to human longevity2, 6. Interestingly, FoxO and Myc 
antagonise each other at numerous levels6, and it will be revealing to explore this relationship in 
the Myc+/- mouse. The activation status of kinases that regulate FoxO members, such as AKT 
and AMPK, were altered in the Myc+/- mice, and they had lower circulating levels of IGF-1, either 
as a consequence of direct Myc action or of feedback in the signalling network. It will be 
informative to investigate the genetic interactions between partial loss-of-function in Myc and 
other longevity interventions. 
 
Myc is notable for being the most highly amplified oncogene in human cancers4. The 
relationships between the mechanisms of cancer prevention and longevity assurance are 
complex2 (Figure 1). For example, cellular senescence forms a potent tumour suppressive 
mechanism but it also contributes to ageing and ageing-related pathologies7, and a similar 
antagonism can be observed at the level of telomere maintenance2. On the other hand, several 
manipulations that moderately increase the activity of tumour supressors and those that block 
oncogenes often extend lifespan. Examples include components of pathways well known in the 
context of ageing, such as Pten in the insulin/IGF signalling cascade8, and genes mostly 
appreciated for their function in tumour suppression, such as the Ink4/Arf locus9, and now Myc3. 
In all cases, extension of lifespan is mostly independent of reduced cancer incidence. Similarly, 
rapamycin, an inhibitor of the TOR kinase, and a pharmacological treatment effective against 
ageing in a number of model organisms including mice, also has anti-cancer activity10. 
This link importantly suggests that some drugs developed to treat cancer could also be used for 
the treatment of other ageing-related diseases (Figure 1). 
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Figure caption 
Figure 1 Relationship between cancer, ageing and potential therapies. 
The complex relationship between mechanisms that suppress or promote cancer and ageing 
raises the question whether therapies designed for cancer treatment can be modified to treat 
other diseases of ageing. 
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